共 50 条
Targeted protein degraders: a call for collective action to advance safety assessment
被引:19
作者:
Jones, Lyn H.
[1
]
Mitchell, Constance A.
[2
]
Loberg, Lise
[3
]
Pavkovic, Mira
[4
]
Rao, Mohan
[5
]
Roberts, Ruth
[6
,7
]
Stamp, Katie
[8
]
Volak, Laurie
[5
]
Wittwer, Matthias B.
[9
]
Pettit, Syril
[2
]
机构:
[1] Dana Farber Canc Inst, Ctr Prot Degradat, Boston, MA 02115 USA
[2] Hlth & Environm Sci Inst, Washington, DC 17602 USA
[3] AbbVie, N Chicago, IL 60064 USA
[4] Bayer, Wuppertal, Germany
[5] Janssen Pharmaceut Companies Johnson & Johnson, San Diego, CA USA
[6] ApconiX, Alderley Edge, England
[7] Univ Birmingham, Dept Biosci, Birmingham, W Midlands, England
[8] Bristol Myers Squibb, New York, NY USA
[9] F Hoffmann La Roche, Roche Innovat Ctr Basel, Basel, Switzerland
关键词:
D O I:
10.1038/d41573-022-00055-9
中图分类号:
Q81 [生物工程学(生物技术)];
Q93 [微生物学];
学科分类号:
071005 ;
0836 ;
090102 ;
100705 ;
摘要:
Targeted protein degraders (TPDs) are emerging classes of therapeutics that have the potential to address difficult drug targets in new ways. In 2021, experts convened to discuss challenges in TPD safety evaluation, and supported supplementing individual efforts to address these challenges with collective development of novel decision frameworks, tools and a shared evidence base. Targeted protein degraders (TPDs) are emerging classes of therapeutics that have the potential to address difficult drug targets in new ways. In 2021, experts convened to discuss challenges in TPD safety evaluation, and supported supplementing individual efforts to address these challenges with collective development of novel decision frameworks, tools and a shared evidence base.
引用
收藏
页码:401 / 402
页数:2
相关论文
共 50 条